| Antigen: |
CD10 (Common Acute Lymphocytic Leukaemia Antigen; CALLA) |
| Relevance: |
CD10 is expressed on B- and T- cell precursors, bone marrow stromal cells, lymphoblastic, Burkitt’s, and follicular germinal center lymphomas, and on cells from patients with chronic myelocytic leukemia (CML). CD10 is a cell surface enzyme that inactivates a variety of peptides. SS2/36 is a marker for Acute Lymphocytic Luekaemia (ALL).
CD10 is widely used for identification of “common” type Acute Lymphocytic Leukaemia (ALL) |
| Clone: |
SS2/36 |
| Subclass: |
IgG1 |
| Applications: |
Western blot, Immunohistochemistry (frozen), FACS |
| Immunogen: |
Common acute lymphoblastic leukaemia cells |
| Reactivity: |
Human |
| Species raised in: |
Mouse |
| Fusion partner: |
NS-1
|
| Recommended growth conditions: |
RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| References: |
Majdic O, Sugita K, Stockinger H, Skrobal A, Knapp W (1987) Comparative evaluation of CD10 antibodies. In McMichael AJ, et al (eds) Leucocyte Typing III, Oxford University Press, Oxford, New York and Tokyo, p 488-489 |
| Notes: |
Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
